Treatment of progressive supranuclear palsy
On 16 July 2016 NeuroTau Inc. obtained US FDA orphan drug designation for tolfenamic acid in the treatment of Progressive Supranuclear Palsy (PSP)
On 16 July 2016 NeuroTau Inc. obtained US FDA orphan drug designation for tolfenamic acid in the treatment of Progressive Supranuclear Palsy (PSP)
On 17 February 2016, NeuroTau partner was granted orphan designation (EU/3/16/1613) by the European Commission for tolfenamic acid for the treatment of progressive supranuclear palsy.
On 16 July 2016 NeuroTau Inc. obtained US FDA orphan drug designation for tolfenamic acid in the treatment of Frontotemporal Dementia (FTD)
On 17 February 2016, NeuroTau Inc partner was granted orphan designation (EU/3/16/1614) by the European Commission for tolfenamic acid for the treatment of behavioural variant frontotemporal dementia.
NeuroTau Inc announces listing of its clinical trial “Evaluation of Tolfenamic Acid in Individuals with Progressive Supranuclear Palsy (PSP)” on ClinicalTrials.gov and intention to begin study in Q1/2021
© NeuroTau, Inc. 2017 | All Rights Reserved